News Releases

News Release

Bioline Expands into Singapore

January 14, 2014 at 7:00 AM EST

CINCINNATI--(BUSINESS WIRE)--Jan. 14, 2014-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the opening of an office in Singapore to support and grow the Bioline business in Singapore and in Asia.

With the opening of the new office; Bioline will provide direct sales, technical support, and training to its existing customers and can also offer a same-day delivery to many of its Singapore-based customers. The investment has included the creation of several Sales and Support positions within the Bioline Singapore office to underpin the increase in service levels. The new location will also be key in the future development of opportunities in the region and provide on-going support to Life Science researchers within Asia.

Marco Calzavara, President of Bioline, commented, “The opening of the Singapore office marks a significant milestone for Bioline, allowing us to support our customers in Singapore with enhanced levels of service for our high-performance PCR products. In addition, Singapore shall serve as a hub for Bioline activities in Asia; supporting the needs of our growing customer-base in Asia.”

Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to open the new Bioline office in Singapore. Our customers can now call us locally, place orders, and receive the goods the same day. This is a further demonstration of our commitment to our life science customers and to bringing innovation and quality products; such as the highly popular SensiFASTTM Real-Time kits and the proven MyTaqTM DNA Polymerase to the research laboratory, clinical diagnostic laboratories, and biotechnology companies.”

Bioline supplies customers in over 30 countries worldwide and serves a large and growing PCR reagents market. The Asian market is projected to grow significantly over the next three to five years. The opening of the Singapore office is intended to provide a platform for Bioline to expand into these fast growing markets and to grow its market share globally.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is

For more information about Bioline, please visit
For more information about Meridian Life Science, Inc., please visit
For more information about Meridian Bioscience, Inc., please visit
Richard L. Eberly,

Source: Meridian Bioscience, Inc.

Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700